HPX Stock Overview
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Hisamitsu Pharmaceutical Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥22.00 |
| 52 Week High | JP¥35.60 |
| 52 Week Low | JP¥22.00 |
| Beta | 0.40 |
| 1 Month Change | -6.78% |
| 3 Month Change | -13.39% |
| 1 Year Change | -10.57% |
| 3 Year Change | -52.99% |
| 5 Year Change | -43.28% |
| Change since IPO | 46.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| HPX | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.9% | 2.5% | 1.8% |
| 1Y | -10.6% | -27.7% | 2.2% |
Return vs Industry: HPX exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: HPX underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| HPX volatility | |
|---|---|
| HPX Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: HPX has not had significant price volatility in the past 3 months.
Volatility Over Time: HPX's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1847 | 2,769 | Kazuhide Nakatomi | www.hisamitsu.co.jp |
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders.
Hisamitsu Pharmaceutical Co., Inc. Fundamentals Summary
| HPX fundamental statistics | |
|---|---|
| Market cap | €1.71b |
| Earnings (TTM) | €84.05m |
| Revenue (TTM) | €852.63m |
20.3x
P/E Ratio2.0x
P/S RatioIs HPX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HPX income statement (TTM) | |
|---|---|
| Revenue | JP¥141.71b |
| Cost of Revenue | JP¥62.74b |
| Gross Profit | JP¥78.97b |
| Other Expenses | JP¥65.00b |
| Earnings | JP¥13.97b |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 184.43 |
| Gross Margin | 55.73% |
| Net Profit Margin | 9.86% |
| Debt/Equity Ratio | 0.4% |
How did HPX perform over the long term?
See historical performance and comparison